Personalis Inc (PSNL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Personalis Inc stock (PSNL) is currently trading at $7.78. Personalis Inc PS ratio (Price-to-Sales) is 11.43. Analyst consensus price target for PSNL is $11.43. WallStSmart rates PSNL as Sell.
- PSNL PE ratio analysis and historical PE chart
- PSNL PS ratio (Price-to-Sales) history and trend
- PSNL intrinsic value — DCF, Graham Number, EPV models
- PSNL stock price prediction 2025 2026 2027 2028 2029 2030
- PSNL fair value vs current price
- PSNL insider transactions and insider buying
- Is PSNL undervalued or overvalued?
- Personalis Inc financial analysis — revenue, earnings, cash flow
- PSNL Piotroski F-Score and Altman Z-Score
- PSNL analyst price target and Smart Rating
Personalis Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Personalis Inc (PSNL) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Personalis Inc (PSNL) Key Strengths (1)
63.89% held by institutions, strong professional interest
Supporting Valuation Data
Personalis Inc (PSNL) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 11.4x annual revenue
Revenue growing slowly at 3.20% annually
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Supporting Valuation Data
Personalis Inc (PSNL) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 8.0/10) while 7 fall into concern territory (avg 2.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (11.43), Price/Book (2.91) suggest expensive pricing. Growth concerns include Revenue Growth at 3.20%, which may limit upside. Profitability pressure is visible in Return on Equity at -35.00%, Operating Margin at -145.70%, Profit Margin at -116.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -35.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 3.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PSNL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PSNL's Price-to-Sales ratio of 11.43x sits near its historical average of 12.02x (58th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 77% below its historical high of 50.56x set in Jun 2019, and 837% above its historical low of 1.22x in Oct 2023. Over the past 12 months, the PS ratio has expanded from ~3.8x, reflecting growing market expectations outpacing revenue growth.
Compare PSNL with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Personalis Inc (PSNL) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Personalis Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 70M with 320% growth year-over-year. The company is currently unprofitable, posting a -116.7% profit margin.
Key Findings
Revenue growing at 320% YoY, reaching 70M. This pace significantly outperforms most DIAGNOSTICS & RESEARCH peers.
Spending 19% of revenue (13M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -116.7% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -22M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Personalis Inc maintain 320%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.11, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Personalis Inc.
Bottom Line
Personalis Inc is a high-conviction growth story with revenue accelerating at 320% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -116.7% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Personalis Inc(PSNL)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Personalis, Inc. is a global cancer genomics company. The company is headquartered in Menlo Park, California.